{
    "clinical_study": {
        "@rank": "136053", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: Lirilumab + Ipilimumab", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab 0.1, 0.3, 1 or 3 mg/kg and Ipilimumab 3 or 10 mg/kg Solution by Intravenous every 3 weeks in the induction phase for a total of 4 doses for 23 weeks and in maintenance phase every 12 weeks for an additional 4 doses for 37 weeks\n\u2022 Dose Escalation"
            }, 
            {
                "arm_group_label": "Arm 2: Lirilumab + Ipilimumab", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab and Ipilimumab Solution by Intravenous dose selected during dose escalation every 3 weeks in the induction phase for a total of 4 doses for 23 weeks and in maintenance phase every 12 weeks for an additional 4 doses for 37 weeks\n\u2022 Cohort Expansion"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and\n      identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with\n      ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors."
        }, 
        "brief_title": "Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "CANCER, NOS", 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Histologic confirmation of one of the following solid tumors that is advanced\n             (unresectable or metastatic) for dose escalation or cohort expansion:Non-Small Cell\n             Lung Cancer (NSCLC), Castrate Resistant Prostate Cancer (CRPC), Melanoma (MEL)\n\n          -  At least one measurable lesion at baseline by Computed tomography  (CT) or Magnetic\n             resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors  (RECIST)\n             1.1 criteria\n\n          -  Biopsies: Subjects in the melanoma cohort must have at least 1 tumor site that can be\n             biopsied at acceptable clinical risk\n\n          -  Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n\n          -  Estimated life expectancy of \u2265 12 weeks\n\n          -  White blood cell (WBC) \u22652000/\u03bcL, Neutrophils \u22651500/\u03bcL, Platelets \u2265 100x1000/\u03bcL,\n             Hemoglobin \u2265 8.5 g/dL, creatinine \u2264 1.5 X upper limit of normal (ULN)  mL/min,\n             Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \u2264 3x ULN\n\n        Exclusion Criteria:\n\n          -  Participation in any prior clinical study with BMS-936558 or ipilimumab that has\n             overall survival listed as a primary/co-primary endpoint\n\n          -  Subjects with known or suspected brain metastasis\n\n          -  Subjects with active autoimmune disease, uncontrolled or significant cardiovascular\n             disease\n\n          -  Prior therapy with anti- Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) antibody or anti-\n             Killer cell immunoglobulin-like receptor (KIR) antibody"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750580", 
            "org_study_id": "CA223-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: Lirilumab + Ipilimumab", 
                    "Arm 2: Lirilumab + Ipilimumab"
                ], 
                "intervention_name": "Lirilumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BMS-986015", 
                    "IPH-2102", 
                    "ANTI-KIR"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm 1: Lirilumab + Ipilimumab", 
                    "Arm 2: Lirilumab + Ipilimumab"
                ], 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "BMS-734016"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Site 0008"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Geoffrey Gibney, Site 0001", 
                    "phone": "813-745-7631"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0010"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0009"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Faber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sarah Cooley, Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University Of Minnesota"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Naiyer Rizvi, Site 0003", 
                    "phone": "646-888-4439"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Ctr"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Erin Bertino, Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jeffrey Infante, Site 0005", 
                    "phone": "877-691-7274"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety as measured by the rate of adverse events, and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to a maximum of 1.4 years (treatment period)"
            }, 
            {
                "measure": "Safety as measured by the rate of adverse events, and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "90 days (follow-up)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750580"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Efficacy will be measured based on immune-related Response Evaluation Criteria for Solid Tumors (irRECIST) 1.1 and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 using Best overall response (BOR), Objective response rate (ORR), Duration of Response (DOR), Progression-Free Survival Rate (PFSR)\nEfficacy will be measured on every 6-12 weeks while on treatment and approximately every 12 weeks during follow-up", 
                "measure": "Efficacy as measured by tumor assessment (per RECIST 1.1 and irRECIST 1.1)", 
                "safety_issue": "No", 
                "time_frame": "Up to 1.4 years (treatment) and 90 days (follow-up)"
            }, 
            {
                "measure": "The maximum observed serum concentration (Cmax) of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "The time of maximum observed serum concentration (Tmax) of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Area under the serum concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Apparent total body clearance (CL) of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Apparent volume of distribution at steady state (Vss) of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Serum half-life (T-HALF) of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Trough observed serum concentration (Cmin) of BMS-986015 and Ipilimumab", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 time points in 18 months"
            }, 
            {
                "measure": "Immunogenicity as measured by the incidence of Ipilimumab and anti-Killer cell immunoglobulin-like receptor (KIR) (BMS-986015) anti-drug antibodies (ADA)", 
                "safety_issue": "Yes", 
                "time_frame": "9 time points in 18 months"
            }, 
            {
                "measure": "Immunohistochemistry on mandatory tumor biopsies based on measures of Tumor infiltrating lymphocyte (TIL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and at week 12 (Induction therapy)"
            }, 
            {
                "measure": "Immunohistochemistry on mandatory tumor biopsies based on Programmed Death Ligand 1 (PD-L1)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and at week 12 (Induction therapy)"
            }, 
            {
                "measure": "Immunohistochemistry on mandatory tumor biopsies based on Human leukocyte antigen (HLA) Class I expression", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and at week 12 (Induction therapy)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}